Revolution Medicines Statistics
Revolution Medicines (42Z) Stock Statistics & Valuation Metrics
Total Valuation
Revolution Medicines has a market cap or net worth of EUR 31.51B. The enterprise value is EUR 41.68B.
- Market Cap
- EUR 31.51B
- Enterprise Value
- EUR 41.68B
Share Statistics
Revolution Medicines has 216,292,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 216,292,330
- Owned by Insiders
- 2.04%
- Owned by Institutions
- 90.42%
Financial Efficiency
Revolution Medicines’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -56.83%.
- Return on Equity (ROE)
- -0.69
- Return on Assets (ROA)
- -0.48
- Return on Invested Capital (ROIC)
- -56.83%
- Return on Capital Employed (ROCE)
- -0.57
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.28M
- Employee Count
- 883
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Revolution Medicines is -17.47. Revolution Medicines’s PEG ratio is 0.35.
- PE Ratio
- -17.47
- PS Ratio
- 174.97
- PB Ratio
- 14.30
- Price to FCF
- -23.99
- Price to Operating Cash Flow
- -24.00
- PEG Ratio
- 0.35
Income Statement
In the last 12 months, Revolution Medicines had revenue of 0 and earned -1.13B in profits. Earnings per share was -5.95.
- Revenue
- 0
- Gross Profit
- -16.56M
- Operating Income
- -1.18B
- Pretax Income
- -1.13B
- Net Income
- -1.13B
- EBITDA
- -1.09B
- Earnings Per Share (EPS)
- -5.95
Cash Flow
In the last 12 months, operating cash flow was -1.43B and capital expenditures -9.45M, giving a free cash flow of -1.44B billion.
- Operating Cash Flow
- -1.43B
- Free Cash Flow
- -1.44B
- Free Cash Flow per Share
- -6.70
Dividends & Yields
Revolution Medicines pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.17%
- Earnings Yield
- -5.45%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- 145.80%
- 50-Day Moving Average
- 171.76
- 200-Day Moving Average
- 140.63
- Relative Strength Index (RSI)
- 30.78
- Average Volume (3m)
- 283
Important Dates
Revolution Medicines upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Revolution Medicines as a current ratio of 7.14, with Debt / Equity ratio of 9.73%
- Current Ratio
- 7.14
- Quick Ratio
- 7.14
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.21
- Interest Coverage Ratio
- -48.80
Taxes
In the past 12 months, Revolution Medicines has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Revolution Medicines EV to EBITDA ratio is -19.49, with an EV/FCF ratio of -24.01.
- EV to Sales
- 175.09
- EV to EBITDA
- -19.49
- EV to Free Cash Flow
- -24.01
- EV to Operating Cash Flow
- -24.17
Balance Sheet
Revolution Medicines has EUR 3.65B in cash and marketable securities with EUR 639.10M in debt, giving a net cash position of EUR 3.01B billion.
- Cash & Marketable Securities
- EUR 3.65B
- Total Debt
- EUR 639.10M
- Net Cash
- EUR 3.01B
- Net Cash Per Share
- EUR 13.93
- Tangible Book Value Per Share
- EUR 10.85
Margins
Gross margin is 95.16%, with operating margin of -852.98%, and net profit margin of -946.82%.
- Gross Margin
- 95.16%
- Operating Margin
- -852.98%
- Pretax Margin
- -948.02%
- Net Profit Margin
- -946.82%
- EBITDA Margin
- -898.20%
- EBIT Margin
- -906.65%
Analyst Forecast
The average price target for Revolution Medicines is EUR 245.62, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 245.62
- Price Target Upside
- 67.94% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 24
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -67.73%
Scores
- Smart Score
- 6
- AI Score
- ―

